Skip to main content

Table 4 SNOT-22 scores grouped by domains

From: Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps

 

Baseline (n = 53)

16 weeks (n = 38)

28 weeks (n = 36)

Rhinologic Symptoms (maximum score = 30)

20.4 (5.85)

8.07 (4.1)

7.52 (4.85)

Extra-Nasal Rhinologic Symptoms (maximum score = 15)

8.76 (3.24)

3.07 (2.4)

2.72 (2.04)

Ear/Facial Symptoms (maximum score = 25)

9.24 (5.72)

3.73 (2.9)

3.97 (4.06)

Psychological Dysfunction (maximum score = 35)

18.58 (8.75)

6.84 (7.71)

7.34 (7.63)

Sleep Dysfunction (maximum score = 25)

15.67 (6.72)

6.57 (6.28)

7.02 (7.26)